[Do fixed ICS/LABA-combinations have advantages in terms of patient-centered parameters?].
Buhl
R
R
III. Medizinische Klinik, Klinikum der Johannes Gutenberg-Universität Mainz, 55131 Mainz. r.buhl@3-med.klinik.uni-mainz.de
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000009:adverse effects; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D019317:Evidence-Based Medicine; D006801:Humans; D010349:Patient Compliance; D010366:Peak Expiratory Flow Rate; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations